X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Genprex gains a worldwide, exclusive license to a patent application and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to a gene therapy, GPX-002, for both Type 1 and Type 2 diabetes.
Lead Product(s): GPX-002
Therapeutic Area: Endocrinology Product Name: GPX-002
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Genprex
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 18, 2023
Details:
University of Pittsburgh grants Genprex a preclinical technology that transforms macrophages, complementary to the GPX-002 diabetes technology. Novel infusion process uses an endoscope and an AAV vector with a glucagon promoter to deliver the Pdx1 + MafA genes to the pancreas.
Lead Product(s): GPX-002
Therapeutic Area: Endocrinology Product Name: GPX-002
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Genprex
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 05, 2023
Details:
Diabetic mice studies have shown that GPX-002, a gene therapy for diabetes, restored normal blood glucose levels for an extended period of time, which could translate to decades in humans.
Lead Product(s): GPX-002
Therapeutic Area: Endocrinology Product Name: GPX-002
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Genprex
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 15, 2022
Details:
Preclinical research in a syngeneic solid tumor mouse model shows that I/ONTAK (E7777 or denileukin diftitox) enhances anti-tumor activity and significantly extends survival benefit of anti-PD-1 therapy.
Lead Product(s): Denileukin Diftitox,Pembrolizumab
Therapeutic Area: Oncology Product Name: I/ONTAK
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Citius Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 22, 2022
Details:
Current SNAP-CAR T therapies are designed to target specific tumor antigens that correspond to a specific cancer indication. This approach has proven effective in certain cancer types but limits the applicability of those CAR T therapies.
Lead Product(s): SNAP-CAR T Cell Therapy,Undisclosed
Therapeutic Area: Oncology Product Name: SNAP-CAR T Cell Therapy
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Coeptis Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 21, 2022
Details:
The treatment, dubbed PiN-21, could offer an affordable, needle-free option for treating early infections of SARS-CoV-2—the novel coronavirus behind COVID.
Lead Product(s): nanobody
Therapeutic Area: Infections and Infectious Diseases Product Name: PiN-21
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2021
Details:
Cell Biology and Developmental Biology in University of Pittsburgh School of Medicine and Astellas will work jointly to evaluate and optimize the drug candidates with an aim to provide new treatment options to help recover and maintain vision in dry AMD patients.
Lead Product(s): AAV-based gene therapy
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 24, 2020
Details:
The researchers reported in the journal Cell that Ab8 is highly effective in preventing and treating SARS-CoV-2 infection in mice and hamsters. In mice and hamsters, Ab8 proved effective in preventing and treating the disease; the journal Cell published the findings.
Lead Product(s): Ab8
Therapeutic Area: Infections and Infectious Diseases Product Name: Ab8
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
